What is VERASTEM ONCOLOGY?
Verastem Oncology operates as a specialized clinical-stage biopharmaceutical entity, primarily focused on the discovery and development of innovative medicines. The company's core competency lies in targeting cancers driven by specific abnormalities within the RAS and MAPK signaling pathways. By focusing on these underlying biological mechanisms, Verastem aims to overcome traditional barriers to treatment, such as drug resistance and disease progression. Its market position is defined by a robust commitment to precision medicine, positioning the firm as a key player in the competitive landscape of targeted cancer therapies.
How much funding has VERASTEM ONCOLOGY raised?
VERASTEM ONCOLOGY has raised a total of $599M across 14 funding rounds:
Stock Offering
$63.3M
Unspecified
$2M
Other Financing Round
$3.9M
Stock Offering
$50.9M
Stock Offering
$25M
Multiple Rounds
$131.1M
Debt
$4.8M
Share Placement
$100M
Debt
$150M
Stock Issuance/Offering (2012): $63.3M featuring Undisclosed
Unspecified (2012): $2M backed by Undisclosed
Other Financing Round (2014): $3.9M with participation from Undisclosed
Stock Issuance/Offering (2015): $50.9M led by Undisclosed
Stock Issuance/Offering (2017): $25M supported by Undisclosed
Debt (2018): $50M featuring Hercules Capital
Stock Issuance/Offering (2018): $38.3M backed by Undisclosed
Stock Issuance/Offering (2018): $42.8M with participation from Consonance Capital
Debt (2020): $4.8M led by Undisclosed
Share Placement (2020): $100M supported by Vivo Capital, RA Capital Management, Venrock Healthcare Capital Partners, Farallon Capital Management, Acuta Capital, Avidity Partners, EcoR1 Capital, and Logos Capital
Debt (2022): $150M featuring Oxford Finance
Key Investors in VERASTEM ONCOLOGY
Longwood Fund
A venture capital firm that creates and invests in science-based companies, partnering with world-class scientific co-founders to develop innovative solutions for significant medical challenges.
MPM Capital
MPM BioImpact manages early-stage venture funds and public impact funds, focusing on converting cutting-edge science into life-saving therapeutics.
Cardinal Partners
A leading venture capital partnership focused exclusively on healthcare investing, specializing in early-stage financing rounds for high-growth companies.
What's next for VERASTEM ONCOLOGY?
Looking ahead, the recent capital injection is expected to accelerate the clinical development of Verastem's lead candidates. The strategic focus will likely remain on optimizing the therapeutic efficacy of its pipeline while exploring potential partnerships to enhance commercialization efforts. As the company moves deeper into its clinical lifecycle, the emphasis will shift toward achieving key regulatory milestones and demonstrating the clinical utility of its targeted therapies in broader patient populations. This phase of development is critical for validating the company's long-term value proposition in the global oncology market.
See full VERASTEM ONCOLOGY company page
